替加环素单药治疗泛耐药鲍曼不动杆菌的疗效观察  

Efficacy Observation of Tigecycline Monotherapy for Pan-resistant Acinetobacter baumannii

作　　者：李鑫[1] 陈洋[1] 王之赫 陆思静[1] 

机构地区：[1]辽宁医学院附属第一医院,辽宁锦州121000

出　　处：《中国药房》2015年第8期1101-1102,共2页China Pharmacy

基　　金：辽宁省科技厅基金资助项目(No.2013225305);辽宁省科技厅基金资助项目(No.2009225010-41)

摘　　要：目的:观察替加环素单药治疗泛耐药鲍曼不动杆菌的临床疗效。方法:采用回顾性分析方法,选择2012年1月-2013年5月我院使用替加环素单药(20例)与经验性头孢哌酮/舒巴坦联合米诺环素(20例)治疗泛耐药鲍曼不动杆菌感染的重症患者临床资料,采用卡方检验,评价其临床疗效。结果:替加环素单药与头孢哌酮/舒巴坦联合米诺环素治疗泛耐药鲍曼不动杆菌的有效率分别为80%、50%(P<0.05)。结论:在治疗泛耐药鲍曼不动杆菌感染临床常用抗菌药物效果不佳时,可以考虑选择替加环素。OBJECTIVE：To observe the clinical efficacy of tigecycline monotherapy for pan-drug resistant Acinetobacter baumannii. METHODS：Clinical data of severe patients with pan-drug resistant A. baumannii infection treated with tigecycline monotherapy（20 cases）or empirical treatment of cefoperazone/sulbactam（20 cases）were analyzed retrospectively in our hospital during Jan.2012-May. 2013. The chi-square test method was used to evaluate its clinical efficacy. RESULTS：Effective rates of tigecycline monotherapy or cefoperazone/sulbactam combined with minocycline were 80% and 50%（P〈0.05）. CONCLUSIONS：In the treatment of pan-resistant A. baumannii infection,tigecycline can be considered when the effect of commonly used antibiotics is poor.

关 键 词：替加环素 泛耐药鲍曼不动杆菌 临床疗效 

分 类 号：R978.1[医药卫生—药品] R969.4[医药卫生—药学]